Back to results
US 8,613,951 B2Granted
Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same
AssigneeBIND Therapeutics, Inc.
InventorsStephen E. Zale, Greg Troiano, Mir Mukkaram Ali, Jeff Hrkach, James Wright
Life of this patent
Estimating the term…
Abstract
The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 1 to about 20 weight percent of a mTOR inhibitor; and about 70 to about 99 weight percent biocompatible polymer.
Claims24
A therapeutic nanoparticle comprising:
- about 5 to about 15 weight percent of a mTOR inhibitor;
- and
- about 50 to about 99 weight percent biocompatible polymer, wherein the biocompatible polymer is a diblock poly(lactic) acid-poly(ethylene)glycol copolymer, wherein said diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic acid) having a number average molecular weight of about 15 to 20 kDa and poly(ethylene)glycol having a number average molecular weight of about 4 to about 6 kDa, wherein the diameter of the therapeutic nanoparticle is about 70 to about 130 nm;
- and
- wherein the particle releases less than about 10% of the mTOR inhibitor over about one minute when placed in a phosphate buffer solution at room temperature.
2 more elements
A therapeutic nanoparticle comprising:
- about 10 to about 20 weight percent of a therapeutic agent selected from the group consisting of sirolimus, temsirolimus, or everolimus;
- and
- a diblock poly(lactic) acid-poly(ethylene)glycol copolymer,
- wherein said diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic acid) having a number average molecular weight of about 15 to 20 kDa and poly(ethylene)glycol having a number average molecular weight of about 4 to about 6 kDa, wherein the diameter of the therapeutic nanoparticle is about 70 to about 130 nm;
- and wherein the particle releases about 0.1 to about 20% therapeutic agent over about one hour when placed in an aqueous solution at 25° C.
2 more elements
A pharmaceutical composition comprising:
- a plurality of nanoparticles each comprising about 4 to about 25 weight percent of a mTOR inhibitor, about 50 to about 99 weight percent of a diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprising poly(lactic acid) having a number average molecular weight of about 15 to 20 kDa and poly(ethylene)glycol having a number average molecular weight of about 4 to about 6 kDa, and having a diameter of about 70 to about 140 nm;
- and
- a saccharide;
- wherein said nanoparticles are stable for at least 3 days when held at 25° C.
1 more element
Dependencies are inferred from the claim text.